MedTrace Logo

Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke

NCT05240560 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-08-09

No results posted yet for this study

Summary

Multicenter, randomized, double blind, parallel-group, placebo-controlled proof of concept study evaluating efficacy and safety of BP1.3656 in patients with fatigue following ischemic stroke.

Conditions

Interventions

DRUG

BP1.3656

Histamine H3 receptor antagonist/inverse agonist

Sponsors & Collaborators

Principal Investigators

  • Claudio Bassetti, MD, Prof. · Inselspital Bern, Department of Neurology, Bern, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-20
Primary Completion
2024-02-08
Completion
2024-02-08

Countries

  • France
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05240560 on ClinicalTrials.gov